$20m for Lutonix's drug-coated balloon tech
This article was originally published in Clinica
Minneapolis, Minnesota-based balloon angioplasty specialist Lutonix has raised $20m in series B financing in a round led by Versant Ventures. Previous investors US Venture Partners and RiverVest Venture Partners also contributed to the fundraising. Lutonix said it will use the new capital for product development activities and to initiate human clinical trials of its drug-coated balloon angioplasty catheter. The first targeted indication for the device will be the treatment and prevention of vascular restenosis.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.